Glycogen storage disease type III CT scan: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Aditya Ganti (talk | contribs) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Abdominal [[computed tomography]] or [[magnetic resonance imaging]] with contrast is performed to screen for evidence of liver cirrhosis, hepatic adenoma, and hepatocellular carcinoma. | Abdominal [[computed tomography]] or [[magnetic resonance imaging]] with contrast is performed to screen for evidence of [[liver cirrhosis]], [[Hepatocellular adenoma|hepatic adenoma]], and [[hepatocellular carcinoma]]. | ||
==CT== | ==CT== | ||
*Abdominal [[computed tomography]] or [[magnetic resonance imaging]] with contrast is performed to screen for:<ref name="KishnaniAustin2010">{{cite journal|last1=Kishnani|first1=Priya S|last2=Austin|first2=Stephanie L|last3=Arn|first3=Pamela|last4=Bali|first4=Deeksha S|last5=Boney|first5=Anne|last6=Case|first6=Laura E|last7=Chung|first7=Wendy K|last8=Desai|first8=Dev M|last9=El-Gharbawy|first9=Areeg|last10=Haller|first10=Ronald|last11=Smit|first11=G Peter A|last12=Smith|first12=Alastair D|last13=Hobson-Webb|first13=Lisa D|last14=Wechsler|first14=Stephanie Burns|last15=Weinstein|first15=David A|last16=Watson|first16=Michael S|title=Glycogen Storage Disease Type III diagnosis and management guidelines|journal=Genetics in Medicine|volume=12|issue=7|year=2010|pages=446–463|issn=1098-3600|doi=10.1097/GIM.0b013e3181e655b6}}</ref> | *Abdominal [[computed tomography]] or [[magnetic resonance imaging]] with contrast is performed to screen for:<ref name="KishnaniAustin2010">{{cite journal|last1=Kishnani|first1=Priya S|last2=Austin|first2=Stephanie L|last3=Arn|first3=Pamela|last4=Bali|first4=Deeksha S|last5=Boney|first5=Anne|last6=Case|first6=Laura E|last7=Chung|first7=Wendy K|last8=Desai|first8=Dev M|last9=El-Gharbawy|first9=Areeg|last10=Haller|first10=Ronald|last11=Smit|first11=G Peter A|last12=Smith|first12=Alastair D|last13=Hobson-Webb|first13=Lisa D|last14=Wechsler|first14=Stephanie Burns|last15=Weinstein|first15=David A|last16=Watson|first16=Michael S|title=Glycogen Storage Disease Type III diagnosis and management guidelines|journal=Genetics in Medicine|volume=12|issue=7|year=2010|pages=446–463|issn=1098-3600|doi=10.1097/GIM.0b013e3181e655b6}}</ref> | ||
**Evidence of liver cirrhosis (nodular hepatic contour and manifestations of portal venous hypertension such as splenomegaly) | **Evidence of [[liver cirrhosis]] (nodular hepatic contour and manifestations of portal venous hypertension such as [[splenomegaly]]). | ||
**Presence of adenomas | **Presence of [[Hepatic adenoma|adenomas]]. | ||
**Evidence of hepatocellular carcinoma | **Evidence of [[hepatocellular carcinoma]]. | ||
*Patients to be screened include: | *Patients to be screened include: | ||
**Pediatric age group once [[adenoma]] is detected on [[ultrasound]] | **Pediatric age group once [[adenoma]] is detected on [[ultrasound]] | ||
| Line 29: | Line 29: | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Metabolic disorders]] | [[Category:Metabolic disorders]] | ||
[[ | [[Category:Radiology]] | ||
Latest revision as of 17:28, 16 January 2018
|
Glycogen storage disease type III Microchapters |
|
Differentiating Glycogen storage disease type III from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glycogen storage disease type III CT scan On the Web |
|
American Roentgen Ray Society Images of Glycogen storage disease type III CT scan |
|
Risk calculators and risk factors for Glycogen storage disease type III CT scan |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
Abdominal computed tomography or magnetic resonance imaging with contrast is performed to screen for evidence of liver cirrhosis, hepatic adenoma, and hepatocellular carcinoma.
CT
- Abdominal computed tomography or magnetic resonance imaging with contrast is performed to screen for:[1]
- Evidence of liver cirrhosis (nodular hepatic contour and manifestations of portal venous hypertension such as splenomegaly).
- Presence of adenomas.
- Evidence of hepatocellular carcinoma.
- Patients to be screened include:
- Pediatric age group once adenoma is detected on ultrasound
- Older patients even if there is no adenoma on ultrasound
- These investigations should be repeated every 6 - 12 months or earlier on the basis of laboratory and clinical findings.
References
- ↑ Kishnani, Priya S; Austin, Stephanie L; Arn, Pamela; Bali, Deeksha S; Boney, Anne; Case, Laura E; Chung, Wendy K; Desai, Dev M; El-Gharbawy, Areeg; Haller, Ronald; Smit, G Peter A; Smith, Alastair D; Hobson-Webb, Lisa D; Wechsler, Stephanie Burns; Weinstein, David A; Watson, Michael S (2010). "Glycogen Storage Disease Type III diagnosis and management guidelines". Genetics in Medicine. 12 (7): 446–463. doi:10.1097/GIM.0b013e3181e655b6. ISSN 1098-3600.